Italia markets close in 6 hours 59 minutes
FTSE MIB
33.727,31 +98,10 (+0,29%) Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,90 +0,79 (+1,01%) Bitcoin EUR
60.640,22 +1.378,20 (+2,33%)
Acticor Biotech SAS (ALACT.PA)
Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
In data: 09:55AM CEST. Mercato aperto.
| Chiusura precedente | 0,3840 |
| Aperto | 0,3840 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,3810 - 0,3900 |
| Intervallo di 52 settimane | 0,2700 - 6,2200 |
| Volume | |
| Media Volume | 72.693 |
| Capitalizzazione | 6,118M |
| Beta (5 anni mensile) | -0,38 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,7300 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 11,50 |
- GlobeNewswire
Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke
ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter of 2024Optimised development plan to register glenzocimab in Europe and the United States projected no later than 2028 Paris, France, September 14, 2023 - 5.45 pm CEST - Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug f
© 2024 Yahoo. Tutti i diritti riservati.